JK 06
Alternative Names: JK-06; SAL-006Latest Information Update: 27 Apr 2026
At a glance
- Originator SalubrisBio
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoprotein stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 17 Apr 2026 Efficacy and adverse event data from phase I/II trial in Solid tumours released by SalubrisBio
- 20 Oct 2025 Efficacy and adverse event data from a phase I/II trial in Solid tumours released by Salubris Biotherapeutics
- 17 Oct 2025 Efficacy and adverse event data from phase I/II trial in Solid tumours were presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)